New hope for heart failure patients with leaky valves?
NCT ID NCT05991284
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study looks at whether adding the drug sacubitril-valsartan to standard care can improve heart function in people with a type of heart failure (preserved ejection fraction) and at least moderate mitral valve leakage. About 84 adults will be randomly assigned to get the drug or continue standard care alone. The main goal is to measure changes in heart pressure and oxygen use during exercise after six months of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ziekenhuis Oost-Limburg
Genk, 3600, Belgium
Conditions
Explore the condition pages connected to this study.